August 31, 2016 3:48 AM ET

Biotechnology

Company Overview of DNAtrix, Inc.

Company Overview

DNAtrix, Inc., a clinical stage biotechnology company, develops virus-driven immunotherapies for cancer. It offers DNX-2401, an oncolytic immunotherapy for glioblastoma; DNX-2440 and DNX-2450, which are armed DNX virus in development for solid tumors; and MYX-135, an oncolytic immunotherapy that is designed to treat hematological malignancies. DNAtrix, Inc. was incorporated in 2005 and is based in Houston, Texas.

2450 Holcombe Boulevard

Suite X+ 200

Houston, TX 77021

United States

Founded in 2005

Phone:

832-930-2401

Fax:

713-715-6826

Key Executives for DNAtrix, Inc.

Chief Executive Officer and Director
Co-Founder
Co-Founder
Compensation as of Fiscal Year 2016.

DNAtrix, Inc. Key Developments

DNAtrix Therapeutics Receives Orphan-Medicine Designation for Oncolytic Immunotherapy Candidate DNX-2401 from European Commission

DNAtrix Therapeutics has secured an orphan-drug designation from the European Commission for its oncolytic immunotherapy candidate DNX-2401. DNX-2401 is a conditionally replicative oncolytic adenovirus designed to target cells defective in the retinoblastoma (Rb) pathway, which is present in many cancers. The lead DNAtrix product candidate received dual fast-track and orphan status from the US FDA in October 2014. The drug is being investigated as a potential treatment option for glioblastoma, a brain tumour that is resistant to conventional therapies. An average of about 25,000 patients is diagnosed with glioblastoma per annum in the United States and Europe. The decision by European regulators to confer orphan status on DNAtrix will allow the US firm to avail of significant regulatory benefits and incentives in terms of reduced fees, scientific advice, and the possibility of securing a 10-year period of market exclusivity, assuming that DNX-2401 is eventually cleared for market authorisation in Europe in the designated indication. DNAtrix has recently completed enrolling patients with recurrent high-grade gliomas for a Phase Ib clinical study in Spain, and is planning a separate European study in newly diagnosed cases in 2016. Merck & Co entered into a research agreement with DNAtrix in October 2015 to evaluate Merck's PD-1 inhibitor Keytruda (pembrolizumab) with DNX-2401 in Phase II trials. The orphan-drug designation for DNX-2401 is considered a promising development for DNAtrix Therapeutics. Securing the designation is not a guarantee that the experimental therapy will prove successful in later-stage safety and efficiency studies. However, the company will be entitled to regulatory benefits, ranging from protocol assistance and reduced fees for regulatory approval in the European Union. This may potentially accelerate the time to market for the drug.

Merck & Company Collaborates with DNAtrix to Study DNX-2401, Keytruda in Glioblastoma

Merck & Company has entered into a collaboration with DNAtrix for an oncology clinical study collaboration to evaluate the efficacy and safety of DNX-2401, DNAtrix's oncolytic immunotherapy in combination with Keytruda. The phase 2 study will be on patients with recurrent glioblastoma, the most aggressive form of brain cancer for which there is no cure.

DNAtriX, Inc. Presents at Leerink Partners Immuno-Oncology Roundtable, Oct-01-2015 02:20 PM

DNAtriX, Inc. Presents at Leerink Partners Immuno-Oncology Roundtable, Oct-01-2015 02:20 PM. Venue: Le Parker Meridien Hotel, New York, New York, United States. Speakers: Frank Tufaro, Chief Executive Officer and Director.

Similar Private Companies By Industry

Company Name Region
20n Labs, Inc. United States
23andMe, Inc. United States
2C Tech Corporation, Inc. United States
3-V Biosciences, Inc. United States
3D Bio Holdings LLC United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content. For inquiries, please contact Capital IQ directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Bloomberg L.P. United States
NYC2012, Inc. United States
Rush University United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact DNAtrix, Inc., please visit www.dnatrix.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.